Novo Nordisk A/S - share repurchase programme
December 02 2024 - 5:45AM
UK Regulatory
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 2 December 2024 – On 11
November 2024, Novo Nordisk initiated a share repurchase programme
in accordance with Article 5 of Regulation No 596/2014 of the
European Parliament and Council of 16 April 2014 (MAR) and the
Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the
"Safe Harbour Rules"). This programme is part of the overall share
repurchase programme of up to DKK 20 billion to be executed during
a 12-month period beginning 6 February 2024.
Under the programme initiated 11 November 2024, Novo Nordisk
will repurchase B shares for an amount up to DKK 3,136,206,122.30
in the period from 11 November 2024 to 3 February 2025.
Since the announcement 25 November 2024, the following
transactions have been made:
|
|
Number of
B shares |
Average
purchase price |
Transaction
value, DKK |
|
Accumulated, last announcement |
831,987 |
|
611,624,426 |
| 25 November
2024 |
79,943 |
750.50 |
59,997,619 |
| 26 November
2024 |
80,000 |
754.08 |
60,326,499 |
| 27 November
2024 |
80,000 |
747.49 |
59,799,251 |
| 28 November
2024 |
72,075 |
748.28 |
53,932,072 |
| 29 November
2024 |
80,000 |
746.83 |
59,746,099 |
|
Accumulated under the programme |
1,224,005 |
|
905,425,967 |
The details for each transaction made under the share repurchase
programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of
22,571,662 B shares of DKK 0.10 as treasury shares, corresponding
to 0.5% of the share capital. The total amount of A and B shares in
the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to
DKK 20 billion during a 12-month period beginning 6 February 2024.
As of 29 November 2024, Novo Nordisk has since 6 February 2024
repurchased a total 21,427,104 B shares at an average share price
of DKK 829.29 per B share equal to a transaction value of DKK
17,769,219,844.
Novo Nordisk is a leading global healthcare company, founded
in 1923 and headquartered in Denmark. Our purpose is to drive
change to defeat serious chronic diseases, built upon our heritage
in diabetes. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 72,000 people
in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com,
Facebook, Instagram,
X, LinkedIn and
YouTube.
Contacts for further information
|
Media: |
|
Ambre
James-Brown
+45 3079 9289
abmo@novonordisk.com
|
Liz
Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com
|
|
Investors: |
|
Jacob
Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com
|
David
Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com
|
Sina
Meyer
+45 3079 6656 azey@novonordisk.com
|
Ida
Schaap Melvold
+45 3077 5649 idmg@novonordisk.com
|
Frederik
Taylor Pitter
+1 609 613 0568
fptr@novonordisk.com
|
|
Company announcement No 92 / 2024
- CA20241202-Safe Harbour
- 20241202 safe harbour transaction details
Novo Nordisk (TG:NOV)
Historical Stock Chart
From Nov 2024 to Dec 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
From Dec 2023 to Dec 2024
